The importance of spontaneously developing collateral vessels to supplement perfusion of tissue rendered ischemic by vascular obstruction was recognized many years ago. However, it was not until potent angiogenesis factors were identified, purified, and produced in sufficient quantities, that the field began its rapid development. In the early 1990s it was first shown that basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) proteins could actually stimulate collateral flow. However, additional studies also demonstrated that the duration of exposure of the vessels to angiogenesis factors was critical, and that the administration of proteins, with their relativly brief half-lives, may pose important practical limitations. The demonstration that gene therapy can improve collateral function presents one of the solutions to the conundrum, since gene therapy can be considered a sophisticated form of a sustained delivery system. The results of several clinical trials have been reported. All involve administration of single angiogenesis agents, and most are Phase I trials. The two studies rising to Phase II status demonstrated no treatment effect on the primary end-point. It may therefore be relevant to consider that the molecular mechanisms responsible for angiogenesis are extraordinarily complex, and an optimal angiogenesis intervention may require a 'multiple factor' strategy. It is important to note that no serious side-effects ascribable to an angiogenesis agent were recognized in these trials. However, angiogenesis agents are potent molecules with multiple activities. It is therefore possible that they might occasionally cause side-effects, some serious. Among these, based on their biologic activities, are neovascularization of non-targeted tissues, expansion and induction of instability of atherogenic plaque, and growth of tumors. In summary, there is ample experimental evidence justifying an optimistic outlook relating to our eventually being successful in enhancing collateral flow to ischemic tissue in a clinical setting. However, we are not there yet, and identification of the optimal angiogenesis strategy is still unclear. Additional experimental work, in parallel with large, carefully controlled clinical trials are needed to continue the exciting advances of the last decade, and to achieve the goal of providing patients with alternative potent therapies to improve collateral flow, and thereby to alleviate their symptoms and perhaps to prolong their lives.
Introduction
ment. These initial 'preangiogenesis era' interventions were surgical and generally were aimed at trying to The functional importance of spontaneously developing establish connections between extracardiac and coronary collateral vessels in supplementing perfusion of the arteries. The strategies included obliterating the pericardial myocardium rendered ischemic by coronary obstruction sac with mechanical abrasion and the addition of asbestos was recognized many years ago, prompting attempts, both powder [1], tacking omentum to ischemic hearts [2,3], experimental and clinical, to enhance collateral developremoving the epicardium [4] , or combining several of these with the addition of implanting the internal mammary artery into the myocardium [5] . Subsequently, phar-macologic strategies were employed in both experimental atrial administration of bFGF, or intracoronary administraand clinical studies in an attempt to revascularize ischemic tion of VEGF proteins daily for 28 days, significantly hearts [6] [7] [8] .
increased collateral flow [29] [30] [31] . Likewise, studies in the However, the field was severely hampered by the lack of rabbit ischemic hind limb model demonstrated that inpotent angiogenesis factors. This was resolved by the tramuscular administration of bFGF protein daily for 2 identification and purification of vascular endothelial weeks significantly improved limb perfusion [32] . growth factor (VEGF) in the late 1970s and in the 1980s
Although such studies demonstrated proof of concept, [9-13], and basic fibroblast growth factor (bFGF, or additional studies also raised issues that still have not been FGF2) and acidic FGF (aFGF or FGF1) in the 1980s resolved. For example, in attempts to determine a clinically [14] [15] [16] [17] [18] . The practical application of these agents to feasible strategy for delivery of protein to enhance collaterexperimental studies in large animal models of ischemia al flow, different durations of intra-arterial protein adhad to await the development of technologies that allowed ministration were studied in the canine myocardial isthe angiogenesis proteins to be produced in sufficient chemia model. While 28 days of administering boluses of quantities, and subsequently the development of DNA VEGF into the left atrium improved collateral flow, 7 days technology and gene delivery techniques so that gene of administration did not [33] ; and while 7, and as little as therapy studies became possible. Once these breakthroughs 2 days of administering bFGF intracoronary improved were achieved, studies exploring the potential of various collateral flow, a single bolus injection did not [34] . These angiogenesis strategies to develop clinically relevant theraresults demonstrated, at least in this model of myocardial peutic approaches to both myocardial and leg ischemia ischemia, that the duration of exposure of the vessels proliferated, so that over the past half-decade the field has supplying the ischemic tissue to angiogenesis factors was moved forward with great momentum.
critical for a therapeutically relevant effect. 125 However, in parallel with substantive scientific contribuAdditional studies employing I-labeled bFGF demontions has been a cacophony of media and 'scientific' hype, strated that route of administration was another critical often making it difficult to distinguish between what factor in determining local tissue uptake [35] , and potenactually has been accomplished relating to a proven tially, therapeutic response. Thus, whereas 3-5% of an clinical strategy, and what we would like to believe has i.c.-administered dose of bFGF was recovered in the been accomplished. And often missing is thoughtful attenmyocardium, only 0.5% of an i.v.-administered dose was tion to the potentially serious complications that might recovered. The most plausible explanation for these findoccur when administering such biologically potent agents ings derives from the fact that myocardial uptake is to patients. Following, therefore, is a brief overview dependent on peak serum concentration; because bFGF has focusing on these issues. a heparin binding domain, considerable first pass uptake in the lungs will occur following i.v. administration (the lungs contain large amounts of heparan sulphates) resulting 2. Experimental and clinical data in a blunted peak serum concentration presented to the myocardium when compared to the very high concen-2.1. Proteins trations presented to the myocardium with bolus injection directly into the coronary artery. Several early studies were published demonstrating that
The biologic consequences of these differences were VEGF, aFGF (FGF1) and bFGF (FGF2) proteins produced demonstrated in angiogenesis studies of the same canine in vitro changes compatible with their having angiogenesis ischemia model. Collateral flow improved with i.c. adpotential [19] [20] [21] [22] [23] . These studies were followed by in vivo ministration of bFGF, but did not increase when the drug work showing these factors actually do stimulate the was given i.v., despite its being given for 1 week [34] . growth of new vessels [19, 24, 25] . The more recent elegant Although similar uptake studies have not been performed genetic studies of vasculogenesis occurring during embryowith VEGF, its 165 isoform (VEGF ) also has a heparin-165 genesis in the mouse add to the now unequivocal evidence binding domain (whereas VEGF does not), suggesting 121 documenting the critical importance of many molecules, that similar results would obtain. including major contributions of VEGF and angiopoietinAnimal studies that appear to be at variance with these 1, to the development of mature, branching blood vessels results have also been reported. Thus, Lopez et al. [36] [26-28] .
delivered VEGF to a porcine model of myocardial 165 That bFGF and VEGF proteins could actually stimulate ischemia (ameroid occlusion of the circumflex coronary the development of collaterals to tissues supplied by an artery) by three different local intracoronary delivery obstructed artery, and in the process augment tissue blood systems (via an InfusaSleeve catheter, via intracoronary flow, was first demonstrated in the early 1990s. In the bolus infusion, and by epicardial implantation of an experiments on myocardial ischemia, a portion of the left osmotic delivery system). VEGF was administered 3 weeks ventricle of dogs was made ischemic by gradual occlusion after ameroid placement, and indices of collateral function of the circumflex coronary artery. The intracoronary or left were assessed at that time (baseline) and 3 weeks later.
Whereas there was no significant improvement in circumdose i.c. administration of an adenoviral vector carrying flex territory perfusion in control pigs, improved circumthe FGF5 transgene into the non-occluded right coronary flex perfusion was demonstrable within each VEGF-treated increased myocardial flow and function. Surprisingly, they group, using paired t-tests to compare pre-and postfound that about 95% first pass myocardial uptake was treatment perfusion values. Though these data are sugachieved with i. No matter how efficient first pass uptake is, a considerstatistically significant difference demonstrable between able proportion of an angiogenesis factor injected into an VEGF groups and the control group. Third, there were artery supplying the target tissue will enter the systemic three deaths in VEGF-treated animals during the invescirculation and thereby expose non-target tissues to its tigation. Elimination of three animals in a small study such biologic effects [43] . While there is no definitive evidence as this could importantly affect the results through selecyet that such systemic spillover will produce serious sidetion bias. Thus, while suggestive, the data from this effects, there is always that possibility (see below). It experiment do not unequivocally demonstrate that a single would therefore appear that if direct intramuscular inbolus i.c. injection of VEGF is capable of increasing jection of the angiogenesis factor, either by the transepicarcollateral flow to a greater extent than that which occurs in dial or transendocardial route, does result in enhanced the absence of therapy.
collateral flow, such an approach might be preferable. Hariawala et al. [38] also reported improved flow in a A protein, injected once intramuscularly, would be similar model. However, this study is flawed by the fact unlikely to persist in the tissue long enough to exert an that intracoronary bolus administration of VEGF (2 mg) important biologic effect [43] . Although multiple injeccaused severe hypotension that led to the acute death of tions of protein might well improve collateral flow [32] , four of eight animals in the treated group; hence, the such a strategy has practical limitations. Therefore, once it surviving animals, which were found to have greater was demonstrated that an adenoviral vector carrying a collateral flow than the untreated controls, may have reporter transgene efficiently expresses its gene product survived only because they had greater intrinsic collateral after intramyocardial injection [44] , this approach to gene flow. These investigators also demonstrated in the rabbit delivery was explored as an approach for gene therapy. hind limb model of ischemia that a single dose of intraProof of concept that intramyocardial injection could femoral administration of bFGF orVEGF improves enhance collateral flow and improve impaired myocardial 165 collateral flow and, surprisingly, that a single i.v. dose of function was demonstrated in a porcine model of myocar-VEGF also improves flow [39, 40] . There are thus dial ischemia. This was achieved by the transepicardial 165 conflicting results reported in the literature relating to injection of an adenoviral vector carrying the VEGF 121 whether a single intra-arterial bolus injection of VEGF or transgene performed following thoracotomy [45] . The bFGF proteins improves collateral flow, and whether feasibility of catheter-based transendocardial delivery of improvement occurs following iv administration, at least angiogenesis genes has recently been shown [46, 47] , for heparin-binding agents.
demonstrating that the direct injection of angiogenesis factors into the myocardium can be accomplished without 2.2. Genes the need of thoracotomy.
Gene therapy presents one of the solutions to the 2.4. Clinical trials possible dosing conundrum, since gene therapy can be considered a sophisticated form of a sustained delivery At the time of this writing the results of several clinical system. Once transfected, the target cell expresses gene trials have been reported. These are summarized in Table 1 product for days, weeks, or longer, depending on the [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] , which shows the results of the coronary artery specific tissue transfected and on the specific vector used. disease (CAD) studies, and studies are Phase I trials -and although some of the and 60 days after VEGF administration. Multiple endauthors suggest that treatment benefit was evident, the points were analyzed with only two of the analyses design of the studies permits no such conclusions to be showing a statistically significant (P,0.05) improvement. drawn. The studies accomplished what Phase I studies are
The authors concluded that the Phase I data support the designed to accomplish -they demonstrated safety and concept that VEGF improves myocardial perfusion at rest. feasibility. The design of only two of the studies rose to a Why were the results of these latter two trials negative Phase II status, as they had most of the elements that -one [53] testing the effects of single bolus i.c. injection would permit at least tentative efficacy conclusions to be of bFGF protein and the other [58] testing the effects of drawn -the studies of Henry et al. [58] , and that of single bolus i.c. injection of VEGF protein (17 or 50 165 Simons et al. [53] . These were randomized, doubleng / kg / min) followed by 4 h i.v. infusions of VEGF (17 165 blinded, and reasonably powered to demonstrate efficacy, or 50 ng / kg / min) delivered during each of 3 days (days 3, at least if a large treatment effect occurred. Interestingly, 6 and 9)? Although, as discussed above, there are conflicteach of these studies demonstrated no treatment effect on ing results reported in the literature as to the efficacy of the primary end-point (treadmill exercise performance).
these agents in regard to their mode of delivery, at least Importantly, these studies showed that exercise performsome animal studies predicted that single dose administraance improved, but it improved in the untreated patients as tion of VEGF or bFGF proteins would not improve much as it did in the treated patients.
collateral flow in patients, and that i.v. administration of It should be pointed out that these negative Phase II VEGF or bFGF would also be ineffective. Alternatively 165 study results followed the prior presentation at national it is possible that the negative results were contributed to meetings of each of these studies in their non-randomized by too small a sample size, by insensitive tests measuring Phase I iterations; each Phase I study was reported as end-point change, or by other as yet unrecognized factors. showing very encouraging positive results [52, 56, 57] .
Finally, the possibility always must be considered that Indeed, to show how misleading non-randomized studies given the inherent complexity of atherosclerotic disease in can be, the exercise-dobutamine / dipyridamole myocardial humans, enhancing collateral function in patients is a more perfusion (SPECT) studies of a subset of the VEGF treated difficult feat to accomplish than it is in experimental Phase I study patients (14 patients) were separately anaanimals, necessitating the development of more sophistilyzed [63] . Studies were conducted before as well as 30 cated strategies. be an excellent strategy to test the concept that it takes the The answer to this question is not entirely clear. Thus, administration of more than a single agent to cause an when an adenoviral vector expressing murine VEGF optimal angiogenesis response. Employing a multifactor 164 was injected into different normal tissues of adult nude approach that is based on a normal cellular response mice [70] , the response was characterized by similar mechanism, such as overexpressing one of the HIF family VEGF-induced effects found in the Ang-1 knockout mice of transcription factors in ischemic cells, offers a reasonstudies [64] [65] [66] [67] [68] [69] -angiogenesis occurred leading to the able chance that necessary and sufficient angiogenesis formation of enlarged, thin-walled vessels that lacked factors will be expressed, and that such expression will supporting pericytes and that were hyperpermeable. These occur in a sequence and concentration-appropriate manner. immature vessels evolved over time, and the type of vessels formed appeared to be tissue specific. In some of 3.
Delivery of cells (or factors attracting cells) that the tissues these vessels evolved into clusters of matureexpress multiple angiogenesis factors appearing muscular arteries and veins -however, in other tissues they formed disorganized vessel tangles
Another multifactor approach is to attract or deliver to (glomeruloid bodies), similar to structures found in vascuischemic tissue cells that nature has imbued with the lar malformations, malignant tumors, and in benign vascucapacity to express multiple angiogenesis factors in approlar tumors. While it was not ascertained what the morpriate sequence and concentration. One type of cellular phological characteristics of vessels would be if VEGF approach is being tested by investigators from the Max 164 were injected into ischemic tissues, these results raise Planck Institute, who have demonstrated the importance of important questions as to whether VEGF, administered as a the monocyte in promoting arteriogenesis [77] [78] [79] . The single agent, can lead to the development of mature monocyte, upon phenotypic differentiation to a tissue functional collateral vessels.
macrophage, expresses such potentially angiogenesis facThe identification of many genes that are involved in tors as VEGF, nitric oxide, MCP-1, and various cytokines. angiogenesis makes it not unreasonable to conjecture that This group has shown in the rabbit hindlimb model of many other as yet unknown angiogenesis signaling casischemia that the administration of agents that increase the cades will be found, and that many of these will not merely targeting of monocytes to ischemic tissue (administration represent redundant pathways, but will be essential to of MCP-1) improves collateral flow.
Our laboratory has used another multifactor cellular approach. We hypothesized that bone marrow cells have angiogenesis properties that will enhance collateral flow in ischemic tissue; in testing this concept we found that in culture these cells do in fact secrete angiogenesis factors, including VEGF, MCP-1 and bFCF, and that when the conditioned medium derived from these cells is applied to endothelial cells, the endothelial cells proliferate, migrate, and form tubes. Most importantly, we found that when autologous bone marrow is injected transendocardially into ischemic porcine myocardium, collateral flow and myocardial function improve significantly [80] . recent work [77] [78] [79] has called attention to the difference between angiogenesis (the sprouting of endothelial cells that the angiogenesis agent be delivered into the site of from existing vessels to form a new capillary network) and ischemia, or whether it must be delivered to the zone in arteriogenesis (the remodeling and expansion of existing which the potential collaterals reside, which could be vessels). Based on these considerations a compelling case distant from the site of ischemia. We believe that arcan be made that it is the process of arteriogenesis, rather teriogenesis probably does play the key role in collateral than the development of capillaries in the ischemic region, enhancement, and therefore that counting capillaries as a that is critical to improved collateral function. If this is means of proving the success of an angiogenesis intervenindeed the case, then an alternative paradigm for therapeution is meaningless. However, we also believe that potic targeting becomes possible, as some of the vessels tential collaterals probably reside throughout the myocarinvolved in arteriogenesis may lie outside the ischemic dium, and that angiogenesis factors, insofar as they are zone.
capable of improving collateral flow, will probably imThis concept is illustrated in Fig. 1 , which shows how prove collateral flow whether delivered to the ischemic ischemia occurring in a relatively distant site could lead to region, the surrounding contiguous non-ischemic region, or the enlargement of potential collaterals that do not carry flow and that do not actually reside within the ischemic tissue. (Such distant collaterals are seen for example, in patients with coarctation of the aorta, in which ischemia occurs in the legs but collaterals develop in the thorax.) Among the multiple genes activated by shear stress are cytokines, MCP-1, adhesion molecules, and NOS. The Max Planck Institute investigators postulate that MCP-1 attracts monocytes to this focus of increased shear stress, the monocytes adhere to the adhesion molecules and then enter the subendothelial space, where they differentiate into macrophages. The macrophages express multiple products, including MCP-1, cytokines, and the angiogenesis factors VEGF and FGF. In this paradigm the monocyte, which is targeted to the small collaterals being subjected to increased shear stress, because of stress- (Fig. 2) . phenotypically differentiate into macrophages, which then express in a Given these concepts, the question arises as to whether sequential and coordinated manner products that predispose to vascular optimal efficacy for enhancing collateral function requires remodeling (arteriogenesis).
both. The enhancement of collateral flow by interventions recent study in which the effects of overexpression of in which angiogenesis factors are delivered locally into the VEGF (achieved by injecting an adenovirus carrying the ischemic region suggests the validity of this belief [49] .
VEGF transgene) in adult mice was investigated [87] . The However, definitive assessment of this important conunmice, as expected, developed elevated circulating levels of drum will be necessary before reliable strategies for VEGF following injection of the adenoviral vector. Howtherapeutic angiogenesis can be definitively developed. In ever, a high percentage died within days, developing addition, we do not as yet know the functional overlap and increased vascular permeability and severe multiple organ the functional differences between the cytokines that edema. induce angiogenesis vs. those that promote arteriogenesis.
Other potential complications based on biological acThis is another issue that will have to be addressed before tivities are the expansion and induction of instability of we will be able to reliably identify the optimal intervenatherogenic plaque, and the growth of tumors. For examtion(s) that will enhance collateral flow.
ple, Flugelman et al. demonstrated an association between unstable angina and the intra-plaque presence of aFGF and bFGF [88] . They suggested that these agents might play a 5. Yellow flags -the potential for deleterious effects role in plaque instability. In addition, the broad range of cells on which the FGF family of agents exert mitogenic For most potent therapeutic interventions, therapeutic effects could result in the growth of cells resident within efficacy is rarely free of the potential for harmful effects to plaques or of malignant cells. occur. The biological activities of most of the angiogenesis Although the direct mitogenic effects of VEGF are agents currently being tested clinically are very potent, and largely limited to endothelial cells, it is of note that VEGF it is likely that the same activities that lead to a therapeutic and its receptors, VEGFR1 and VEGFR2 (flt-1 and Flk-1), effect could also cause unwanted side effects. It is thereare overexpressed in atherosclerotic lesions [89] . Morefore probable that some side effects consequent to the over, a number of non-endothelial tumor cells have been cellular effects of these agents will inevitably occur. If this found to possess low levels of functional VEGFR-1 and is true, then the critical question we will have to address in VEGFR-2 [90]. Also of possible relevance is the fact that large clinical trials is whether the incidence of these risks the uterus possesses functional VEGF receptor tyrosine is sufficiently low so that the risks will be outweighed by kinases [91] , and that VEGF is mitogenic for uterine the therapeutic benefits. smooth muscle. These observations raise the possibility Among the side effects that might occur as a result of that the atherosclerotic lesion, certain tumors, and the the biologic effects of these agents is the development of common leiomyoma (fibroid), could at least theoretically new blood vessels in non-targeted tissues, a complication respond to direct exogenous stimulation by VEGF. that would be particularly devastating if it were to occur, There is also increasing evidence suggesting that growth for example, in the retina. It is possible that this particular of microvessels into plaque or tumors, through angiocomplication may not develop unless a tissue is 'primed' genesis processes, is critical to growth of both tumor and to respond with an angiogenesis response. That is, quiesplaque [92] [93] [94] [95] [96] [97] . Thus, microvascular angiogenesis per se, cent cells have low constitutive expression of receptors for an activity inherent in most angiogenesis factors, could the VEGF and FGF family of agents -thus, unless the predispose to plaque or tumor growth. In addition, the tissue is exposed to very high doses of the ligands for potent vascular permeability effect of VEGF could result prolonged periods, it is possible that normal tissue is in exposing a plaque or tumor to many cytokines and resistant to the neovascularization effects of angiogenesis growth factors that normally are confined to the plasma, factors, a result suggested by the study by Banai et al. [81] .
and through this indirect mechanism stimulate their In this regard, a patient with diabetic retinopathy does have growth. vascular cells that are 'primed,' insofar as it has been It must be emphasized that there have been no concludemonstrated that there are increased levels of one of the sive reports in clinical studies demonstrating that angioreceptors for VEGF [82] [83] [84] .
genesis agents actually induce new tumor development, Other VEGF-specific complications could develop as a increase growth of in situ tumors, or increase plaque size. result of the potent activity of VEGF as an inducer of However, several experimental studies have demonstrated vascular permeability [10] [11] [12] [13] [14] 85, 86] . Although angiogenthat prolonged exposure of skeletal muscle or myocardium esis and vascular permeability might be considered two to high local levels of VEGF or the FGF family of peptides separate biological activities, it is also possible that the can cause hemangioma-like tumors and vascular malvascular permeability properties of VEGF are essential for formations [81, 89, [98] [99] [100] [101] [102] [103] [104] [105] , and can increase neointimal angiogenesis to occur. development [106] [107] [108] [109] . Whatever the interrelation between these two actions, if
Experimental studies have also demonstrated that high vascular permeability increases in tissues other than the doses of bFGF can lead to the development of thromtissue targeted for angiogenesis, serious consequences bocytopenia and renal toxicity [51] . In addition, the could accrue. That this could occur was demonstrated in a immune surveillance system is not normally exposed to large amounts of these proteins. It is therefore possible that delivering the factor, does optimization of response require antibodies can develop to these cytokines, and that these a multiple-factor strategy, what is the optimal delivery could either impair the efficacy of repeated administration strategy, are there as yet unforeseen obstacles to overcome, of the agents, or even possibly lead to immunopathogenic and will there be serious side effects? processes. It should also be noted that one of the clinical As far as the latter question is concerned, as noted, the trials in progress employs FGF2 of porcine origin [52, 53] ; angiogenesis agents being tested have potent biological although the high homology between the FGFs in different activities and thus certainly have the potential for such species makes it unlikely that recognition of non-self effects. So too, in the case of gene therapy using viral protein will occur, this certainly is not beyond the realm of vectors, do the vectors themselves. It is thus highly possibility.
unlikely that trials will be totally free of serious complica-FGF and VEGF proteins, administered acutely, can tions. The terms of the argument will probably best be produce hypotension through, at least in part, a nitric framed by risk vs. benefit considerations: therefore, careoxide-mediated pathway [110] [111] [112] and, in the case of fully controlled large clinical trials must be completed to FGF2, through a potassium channel-mediated mechanism ascertain whether the incidence of serious complications is [113] . The hypotensive effect has resulted in the death of sufficiently low such that the attendant risks of therapy are pigs that had chronic myocardial ischemia and that were outweighed by the benefits attained. In the end, as scitreated with the intracoronary injection of VEGF protein entists we must be vigilant that we are not seduced by 165 [38] , and in a prolonged hypotensive episode of a patient hype, and that we judge the merits of this potential entered into a Phase I study testing the safety of inimportant and novel therapeutic approach to obstructive tracoronary administration of bFGF [51] . This complicaarterial disease in a dispassionate and objective manner. tion appears to occur only when high systemic levels of bFGF and VEGF develop rapidly. Thus, it would appear to be of no or little concern if bFGF and VEGF proteins are References not administered rapidly and of no concern when the factors are given as genes -which express the proteins atherosclerosis is a complex disease, and it is not clear 
